Key result
Women with hyperandrogenic PCOS phenotypes had substantially higher central fat accumulation indices, including a mean lipid accumulation product of 1802.63 compared to 624.19 in non-hyperandrogenic PCOS.
Why the study?
Women with PCOS have elevated risks of cardiovascular risk factors, insulin resistance, and metabolic syndrome, but the variation in central fat accumulation indices across different PCOS phenotypes required evaluation.
Do central fat accumulation indices differ between hyperandrogenic and non-hyperandrogenic phenotypes in women with polycystic ovary syndrome?
Cross-Sectional (n=100)
No
Do central fat accumulation indices differ between hyperandrogenic and non-hyperandrogenic phenotypes in women with polycystic ovary syndrome?
Absolute Event Rate: 1802.63% vs 624.19%
Hyperandrogenic PCOS phenotypes are associated with significantly higher central fat accumulation indices (BMI, VAI, LAP) compared to non-hyperandrogenic phenotypes, suggesting a higher cardiometabolic risk profile requiring closer monitoring.
Hyperandrogenic PCOS phenotypes may signal higher cardiometabolic risk; leaves open whether phenotype-specific monitoring improves outcomes.
Women with PCOS remain at a high risk of developing cardiovascular risk factors, insulin resistance, and metabolic syndrome, risk being more in obese women. Monitoring of these may be done using the central fat indices, which are inexpensive and simple. The objective of the study was to evaluate the various central fat accumulation indices amongst the different polycystic ovary syndrome phenotypes. Method: 100 women aged 18-40 year fulfilling Rotterdam criteria for diagnosis of PCOS were selected. Height, weight, waist circumference and lipid profile were measured and BMI, Lipid accumulation product and Visceral adiposity index were calculated. Body Fat Percentage was measured by the Body Fat Analyser using the bioelectrical impedance method. Data was analysed and conclusions drawn. Results: Women with hyperandrogenic PCOS [phenotypes A (HA+OD+PCO), B(HA+OD), C(HA+PCO)] (33. 3% of total) presented with raised central fat accumulation indices including BMI (mean:25. 04), BFA (mean: 29. 85), VAI (mean:182. 06) and LAP (mean:1802. 63), compared with women with non-hyperandrogenic PCOS [phenotype D (OD+PCO)] (67% of total); BMI (mean:20. 85), BFA (mean:22. 94), VAI (mean:128. 4) and LAP (mean:624. 19). Amongst women with hyperandrogenic PCOS, the central fat accumulation indices were maximally raised in phenotype A. Conclusion: Though all women with PCOS should be targeted for prevention, screening, and management of cardiometabolic features, women with hyperandrogenic PCOS should be monitored more closely since they tend to have raised central fat accumulation indices compared with non-hyperandrogenic PCOS.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2022) conducted a cross-sectional in Polycystic ovary syndrome (n=100). Hyperandrogenic PCOS phenotypes vs. Non-hyperandrogenic PCOS phenotype was evaluated on Lipid accumulation product (LAP). Women with hyperandrogenic PCOS phenotypes had substantially higher central fat accumulation indices, including a mean lipid accumulation product of 1802.63 compared to 624.19 in non-hyperandrogenic PCOS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: